Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Yen on slippery ground as Yellen, Trump transition news boost risk appetite

11/23/2020 | 07:25pm EST

* Graphic: World FX rates in 2020 https://tmsnrt.rs/2RBWI5E

TOKYO, Nov 24 (Reuters) - The yen was on the back foot while riskier currencies were supported on Tuesday on rising optimism following news U.S. President-elect Joe Biden is expected to tap former Federal Reserve Chair Janet Yellen as U.S. Treasury Secretary.

Also underpinning the risk-on mood, President Donald Trump gave the head of the General Services Administration the go-ahead to proceed with a transition for Biden's administration despite plans to continue with legal challenges.

Yellen has called for increased government spending to boost the U.S. economy out of a deep recession brought on by the coronavirus and has frequently cited growing economic inequality in the United States as a threat to America's values and its future.

"One thing is for sure and that is there is unlikely to be as many Fed-Treasury spats," said Chris Rupkey, chief financial economist at MUFG Union Bank in New York.

"Those Fed lending facilities for municipal funding, the corporate bond market and Main Street will be coming back quickly after the December 31 expiration date."

Last week U.S. Treasury Secretary Steven Mnuchin let some of the Fed's lending programmes expire at the end of this year, opening a feud with the Fed, which said those emergency facilities are important to support the economy.

The safe-haven yen traded at 104.49 per dollar, having slipped about 0.6% overnight.

The U.S. dollar, which tends to weaken against riskier, less liquid currencies on positive market sentiment, also flirted near 12-week lows, though it has managed to find some technical support.

The dollar's index recovered a touch to 92.530 after dropping to 92.013 on Monday, the lowest since Sept. 1. A conclusive break on the dollar index below support at around 92 could bring about a fresh downturn, analysts said.

The U.S. currency's safe-haven appeal was also dented after AstraZeneca said on Monday that its COVID-19 vaccine could be about 90% effective and it would prepare to submit data to authorities around the world that have a framework for conditional or early approval.

The euro was flat at $1.18395, lacking momentum to clear a hurdle at $1.19.

The Australian dollar ticked up 0.15% to $0.7295 while the New Zealand dollar also edged 0.10% higher to test a two-year high of $0.6967 hit on Monday.

The British pound held firm near a 12-week high against the dollar and six-month high versus the euro, propped up by bets Britain and the European Union would clinch a Brexit trade deal.

London and Brussels this week continue their negotiations to agree a deal on their future trading relationship, though time is now running very short as Britain's post-Brexit transition period ends in fewer than six weeks.

The pound stood at $1.3330, having hit a high of $1.3396 on Monday. Against the euro, it traded at 0.8887 to the euro, near its six-month high touched about two weeks ago. (Reporting by Hideyuki Sano Editing by Shri Navaratnam)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.78% 7722 Delayed Quote.4.62%
AUSTRALIAN DOLLAR / CANADIAN DOLLAR (AUD/CAD) 0.00% 0.97977 Delayed Quote.0.30%
AUSTRALIAN DOLLAR / JAPANESE YEN (AUD/JPY) 0.28% 79.912 Delayed Quote.0.55%
AUSTRALIAN DOLLAR / NEW ZEALAND DOLLAR (AUD/NZD) 0.17% 1.08186 Delayed Quote.0.88%
AUSTRALIAN DOLLAR / SWISS FRANC (AUD/CHF) -0.12% 0.6838 Delayed Quote.0.72%
AUSTRALIAN DOLLAR / US DOLLAR (AUD/USD) 0.08% 0.76897 Delayed Quote.-0.14%
BRITISH POUND / AUSTRALIAN DOLLAR (GBP/AUD) 0.25% 1.77178 Delayed Quote.-0.53%
BRITISH POUND / JAPANESE YEN (GBP/JPY) 0.53% 141.593 Delayed Quote.-0.05%
CANADIAN DOLLAR / JAPANESE YEN (CAD/JPY) 0.27% 81.559 Delayed Quote.0.31%
EURO / AUSTRALIAN DOLLAR (EUR/AUD) 0.30% 1.57618 Delayed Quote.-1.03%
EURO / BRITISH POUND (EUR/GBP) 0.06% 0.88957 Delayed Quote.-0.48%
EURO / JAPANESE YEN (EUR/JPY) 0.58% 125.961 Delayed Quote.-0.46%
EURO / US DOLLAR (EUR/USD) 0.36% 1.21212 Delayed Quote.-1.12%
JAPANESE YEN / SWISS FRANC (JPY/CHF) -0.29% 0.8553 Delayed Quote.0.07%
NEW ZEALAND DOLLAR / JAPANESE YEN (NZD/JPY) 0.11% 73.862 Delayed Quote.-0.22%
US DOLLAR / JAPANESE YEN (USD/JPY) 0.20% 103.916 Delayed Quote.0.70%
All news about ASTRAZENECA PLC
01:57pPeru says Sinopharm, Pfizer seek approval for their COVID-19 vaccines
01:43pASTRAZENECA : India to start COVID vaccine exports on Wednesday
01:37pASTRAZENECA : India to start COVID vaccine exports on Wednesday
11:35aBrussels targets vaccinating at least 70% of EU adults by summer
07:45aASTRAZENECA : India's homegrown vaccine developer warns some to avoid shot
07:31aJapan has pre-ordered COVID-19 vaccine doses for more than four times its pop..
06:44aSputnik-AstraZeneca vaccine trials to start in February, says R-Pharm
06:38aPhilippines to buy 20 million Moderna vaccine doses as COVID-19 cases rise
05:00aASTRAZENECA : Thailand defends royal company's role in vaccine strategy
04:39aASTRAZENECA : Thailand defends royal company's role in vaccine strategy
More news
Financials (USD)
Sales 2020 26 399 M - -
Net income 2020 2 970 M - -
Net Debt 2020 13 223 M - -
P/E ratio 2020 40,8x
Yield 2020 2,71%
Capitalization 137 B 137 B -
EV / Sales 2020 5,68x
EV / Sales 2021 4,91x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 126,16 $
Last Close Price 104,06 $
Spread / Highest target 50,0%
Spread / Average Target 21,2%
Spread / Lowest Target -19,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG1.93%303 276
NOVARTIS AG1.65%217 178
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993